This study will examine whether changing the bacteria in the gut through a fecal microbial transplant (FMT) can affect the autoimmune process that leads to the development of multiple sclerosis (MS). Using oral capsules approved by the Food and Drug Administration (FDA) for other uses, we will transfer fecal material from healthy persons to persons with MS. The FDA has granted permission for this investigational pilot study.

The PRC is conducting this study in collaboration with neurologist Joseph Guarnaccia, MD of the Multiple Sclerosis Treatment Center (MSTC) at Griffin Hospital, who is the principal investigator.

Each participant will make 8 visits to Griffin Hospital in Derby, CT. These will include: a clinical screening; a single procedure of 30 FMT capsules taken by mouth; and 5 other visits for blood and stool samples, medical exams, and surveys. FMT capsules and all study procedures and tests will be provided free of charge.

Study participants must: (1) be 18 to 55 years of age; (2) have been clinically diagnosed as having MS; (3) be able to walk with without stopping to rest for up to 100 meters (about 300 feet) or able to walk 20 meters (about 60 feet) without stopping to rest while using 2 canes, 2 crutches, or a walker; (4) not be on immunotherapy (except for interferon beta or glatiramer acetate); and (5) be willing to visit Griffin Hospital 8 times over a 4-month period.